Patents by Inventor Per Borgström

Per Borgström has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treatment of prostate carcinoma
    Patent number: 10577315
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 3, 2020
    Assignee: PELLFICURE PHARMACEUTICALS, INC.
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20190169122
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: September 28, 2018
    Publication date: June 6, 2019
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • Treatment of prostate carcinoma
    Patent number: 10245240
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 2, 2019
    Assignee: PELLFICURE PHARMACEUTICALS, INC.
    Inventor: Per Borgström
  • NOVEL TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20180296500
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: June 21, 2018
    Publication date: October 18, 2018
    Inventor: Per Borgström
  • Compositions and methods for treatment of prostate carcinoma
    Patent number: 10093620
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 9, 2018
    Assignee: PELLFICURE PHARMACEUTICALS, INC.
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE
    Publication number: 20180221306
    Abstract: Disclosed herein are pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.
    Type: Application
    Filed: March 15, 2018
    Publication date: August 9, 2018
    Inventors: Per Borgström, Adrian Chrastina, Veronique Baron
  • NOVEL TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20180116977
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 3, 2018
    Inventor: Per Borgström
  • Treatment of prostate carcinoma
    Patent number: 9877932
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: January 30, 2018
    Assignee: Pellficure Pharmaceuticals, Inc.
    Inventor: Per Borgström
  • COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20170283374
    Abstract: Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 5, 2017
    Inventors: Per Borgström, Adrian Chrastina, Veronique Therese Baron, Parisa Abedinpour
  • NOVEL TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20170258744
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: January 13, 2017
    Publication date: September 14, 2017
    Inventor: Per Borgström
  • Treatment of prostate carcinoma
    Patent number: 9655868
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 23, 2017
    Assignee: Pellficure Pharmaceuticals, Inc.
    Inventor: Per Borgström
  • NOVEL THERAPY FOR PROSTATE CARCINOMA
    Publication number: 20160022606
    Abstract: Disclosed herein are methods of inhibiting or delaying the growth of androgen-dependent prostate cancer, and/or inhibiting or delaying the onset of castration-resistant prostate cancer (CRPC) by administering naphthoquinone analogs, such as plumbagin, and specified hormone therapy agents, including selective inhibitors of 17,20-lyase activity of CYP 17.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 28, 2016
    Inventor: Per BORGSTROM
  • NOVEL TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20150352060
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: August 18, 2015
    Publication date: December 10, 2015
    Inventor: Per Borgström
  • Treatment of prostate carcinoma
    Patent number: 9132105
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: September 15, 2015
    Assignee: Pellficure Pharmaceuticals, Inc.
    Inventor: Per Borgström
  • NOVEL TREATMENT OF PROSTATE CARCINOMA
    Publication number: 20130219528
    Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.
    Type: Application
    Filed: August 3, 2011
    Publication date: August 22, 2013
    Applicant: Pellficure Pharmaceuticals, Inc.
    Inventor: Per Borgström
  • Myeloid colony stimulating factor and uses thereof
    Publication number: 20110212074
    Abstract: The identification of the HYAL 1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5-may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: April 29, 2011
    Publication date: September 1, 2011
    Inventors: Gregory I. Frost, Per Borgstrom
  • ECTOPIC, ORTHOTOPIC MODEL FOR REVASCULARIZATION AND TUMOR ASSESSMENT
    Publication number: 20110173709
    Abstract: Improved vascularization and tumor models, comprising a test animal having a dorsal skin window chamber, and an exogenous tissue sample implanted ectopically in the skin within the window chamber, are described, as are methods of using the models.
    Type: Application
    Filed: February 29, 2008
    Publication date: July 14, 2011
    Inventors: Jan E. Schnitzer, Philip Oh, Per Borgstrom
  • Inhibition of Antigen Presentation with Poorly Catabolized Polymers
    Publication number: 20100331279
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 30, 2010
    Inventors: Gregory I. Frost, Per Borgstrom
  • Inhibition of antigen presentation with poorly catabolized polymers
    Patent number: 7786096
    Abstract: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: August 31, 2010
    Assignee: Halozyme, Inc.
    Inventors: Greogry I. Frost, Per Borgstrom
  • Myeloid Colony Stimulating Factor and Uses Thereof
    Publication number: 20100184845
    Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.
    Type: Application
    Filed: April 1, 2010
    Publication date: July 22, 2010
    Inventors: Gregory I. Frost, Per Borgstrom